Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke

Stroke

Volumn 37, Issue 7, 2006, Pages 1798-1804

  Tanne, David ^a,e   Macko, Richard F ^b   Lin, Yan ^c   Tilley, Barbara C ^c   Levine, Steven R ^d  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e SHEBA MEDICAL CENTER   (Israel)

Author keywords

Hemostasis; Stroke, acute; Thrombolysis

Indexed keywords

FIBRINOGEN; RECOMBINANT PLASMINOGEN ACTIVATOR; THROMBIN ANTITHROMBIN COMPLEX; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; ANTITHROMBIN III; ANTITHROMBIN III PROTEASE COMPLEX; ANTITHROMBIN III-PROTEASE COMPLEX; FIBRINOLYTIC AGENT; PEPTIDE HYDROLASE; RECOMBINANT PROTEIN; THROMBIN;

ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FIBRINOLYSIS; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PLASMA; PRIORITY JOURNAL; RISK; SAMPLE; TREATMENT OUTCOME; ACUTE DISEASE; BIOSYNTHESIS; BLOOD; BRAIN ISCHEMIA; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EPIDEMIOLOGY; FIBRINOLYTIC THERAPY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

ACUTE DISEASE; ANTITHROMBIN III; BRAIN ISCHEMIA; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DOUBLE-BLIND METHOD; FIBRINOGEN; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HEMOSTASIS; HUMANS; MULTICENTER STUDIES; PEPTIDE HYDROLASES; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; THROMBIN; THROMBOLYTIC THERAPY; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 33745955858     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000226897.43749.27     Document Type: Article

References (26)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1588.
2. Parsons MW, Barber PA, Chalk J, Darby DG, Rose S, Desmond PM, Gerraty RP, Tress BM, Wright PM, Donnan GA, Davis SM. Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol. 2002;51:28-37.
3. Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology. 2002;59:862-867.
4. Collet JP, Montalescot G, Vicaut E, Ankri A, Walylo F, Lesty C, Choussat R, Beygui F, Borentain M, Vignolles N, Thomas D. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation. 2003;108:391-394.
5. Fassbender K, Dempfle CE, Mielke O, Schwartz A, Daffertshofer M, Eschenfelder C, Dollman M, Hennerici M. Changes in coagulation and fibrinolysis markers in acute ischemic stroke treated with recombinant tissue plasminogen activator. Stroke. 1999;30:2101-2104.
6. Marti-Fabregas J, Borrell M, Cocho D, Belvis R, Castellanos M, Montaner J, Pagonabarraga J, Aleu A, Molina-Porcel L, Diaz-Manera J, Bravo Y, Alvarez-Sabin J, Davalos A, Fontcuberta J, Marti-Vilalta JL. Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PA. Neurology. 2005;65:366-370.
7. Gulba DC, Barthels M, Westhoff-Bleck M, Jost S, Rafflenbeul W, Daniel WG, Hecker H, Lichtlen PR. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction: relevance for the success of therapy. Circulation. 1991;83:937-944.
8. Scharfstein JS, Abendschein DR, Eisenberg PR, George D, Cannon CP, Becker RC, Sobel B, Cupples LA, Braunwald E, Loscalzo J, for the TIMI-5 Investigators. Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction: Thrombolysis in Myocardial Infarction. Am J Cardiol. 1996;78:503-510.
9. Ray KK, Morrow DA, Gibson CM, Murphy S, Antman EM, Braunwald E, for the ENTIRE-TIMI 23 Study Group. Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: an ENTIRE-TIMI 23 Substudy. Eur Heart J. 2005;26:440-446.
10. Eisenberg PR, Sobel BE, Jaffe AS. Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. J Am Coll Cardiol. 1992;19:1065-1069.
11. Grotta JC, Welch KM, Fagan SC, Lu M, Frankel MR, Brott T, Levine SR, Lyden PD. Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial. Stroke. 2001;32:661-668.
12. The NINDS rt-PA Stroke Study Group. Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. Stroke. 2000;31:2912-2919.
13. Patel SC, Levine SR, Tilley BC, Grotta JC, Lu M, Frankel M, Haley EC Jr, Brott TG, Broderick JP, Horowitz S, Lyden PD, Lewandowski CA, Marler JR, Welch KM. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA. 2001;286:2830-2838.
14. Fleiss JL. Analysis of data from multiclinic trials. Control Clin Trials. 1986;7:267-275.
15. Genser N, Lechleitner P, Maier J, Dienstl F, Artner-Dworzak E, Puschendorf B, Mair J. Rebound increase of plasminogen activator inhibitor type 1 after cessation of thrombolytic treatment for acute myocardial infarction is independent of type of plasminogen activator used. Clin Chem. 1998;44:209-214.
16. Chandler WL, Alessi MC, Aillaud MF, Henderson P, Vague P, Juhan-Vague I. Clearance of tissue plasminogen activator (tPA) and tPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated tPA antigen in patients with high PAI-1 activity levels. Circulation. 1997;96:761-768.
17. Macko RF, Kittner SJ, Epstein A, Cox DK, Wozniak MA, Wityk RJ, Stern BJ, Sloan MA, Sherwin R, Price TR, McCarter RJ, Johnson CJ, Earley CJ, Buchholz DW, Stolley PD. Elevated tissue plasminogen activator antigen and stroke risk: the Stroke Prevention In Young Women Study. Stroke. 1999;30:7-11.
18. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 1994;343:940-943.
19. Suo Z, Citron BA, Festoff BW. Thrombin: a potential proinflammatory mediator in neurotrauma and neurodegenerative disorders. Curr Drug Targets Inflamm Allergy. 2004;3:105-114.
20. Tanne D, Benderly M, Goldbourt U, Boyko V, Brunner D, Graff E, Reicher-Reiss H, Shotan A, Mandelzweig L, Behar S. A prospective study of plasma fibrinogen levels and the risk of stroke among participants in the Bezafibrate Infarction Prevention Study. Am J Med. 2001;111:457-463.
21. Di Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke. 2001;32:133-138.
22. Takano S, Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases. Blood. 1990;76:2024-2029.
23. Olivot JM, Labreuche J, Aiach M, Amarenco P. Soluble thrombomodulin and brain infarction: case-control and prospective study. Stroke. 2004;35:1946-1951.
24. Lewis MR, Callas PW, Jenny NS, Tracy RP. Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples. Thromb Haemost. 2001;86:1495-1500.
25. Grotta JC. Adding to the effectiveness of intravenous tissue plasminogen activator for treating acute stroke. Circulation. 2003;107:2769-2770.
26. Liu D, Cheng T, Guo H, Fernandez JA, Griffin JH, Song X, Zlokovic BV. Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med. 2004;10:1379-1383.